Results from phase 1 study, using PRT3789 for the treatment of patients with SMARCA4 mutated advanced tumors, expected in the 2nd half of 2024. Results from phase 1 study, using PRT2527 for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results